TriSalus today said it appointed Scott Davie as chief financial officer.
Davie will be responsible for overseeing research and development of the company’s intravascular infusion systems. He will report directly to president and CEO Mary Szela.
“We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at TriSalus. Our PEDD-based products have tremendous promise for treating solid tumors, and under his knowledge and leadership skills, we’re poised to help lead a transformation in cancer care,” Szela said in a news release. “Additionally, his experience in the U.S., Canadian, and Japanese markets is essential to supporting our global development efforts.”
Prior to joining the company, Davie held a number of leadership roles at Medtronic. He has more than 25 years of experience in the medical device industry.
“As someone who’s watched cancer cut family members’ lives short, I am thrilled to be part of the TriSalus team and embrace the opportunity to dramatically improve therapeutic delivery and outcomes for these cancer patients,” said Davie.
Davie’s appoint comes after TriSalus appointed chief financial officer Rajesh Mistry on June 2.